ECA
IBB icon

Elevated Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Elevated Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$761 Hold
4
– – ﹤0.01% 771
2026
Q1 		$675 Hold
4
– – ﹤0.01% 767
2025
Q4 		$675 Buy
+4
New +$650 ﹤0.01% 741

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Elevated Capital Advisors's IBB Position: Q2 2026 in Review

Elevated Capital Advisors held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 4 shares worth $761. The position accounts for ﹤0.01% of the portfolio, ranked #771.

Elevated Capital Advisors first reported a position in IBB in Q4 2025 and has held it in 3 quarters since. 955 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Elevated Capital Advisors held 4 shares of iShares Biotechnology ETF worth $761 as of Q2 2026.
  • Elevated Capital Advisors left its iShares Biotechnology ETF share count unchanged in Q2 2026.
  • iShares Biotechnology ETF made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #771 holding.
  • Elevated Capital Advisors first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 3 quarters since.
  • 955 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.